Longevity & AgingBuntanetap Shows Cognitive Gains in Early Alzheimer's Patients With Key Biomarker
A new trial published in Nature NPJ Dementia tested buntanetap, an Alzheimer's drug made by Annovis Bio, in 351 patients over 12 weeks. While it missed its primary endpoints overall, patients in earlier disease stages who tested positive for a biomarker called pTau217 showed statistically significant cognitive improvements. Unlike most Alzheimer's drugs that target a single protein, buntanetap works upstream, blocking production of multiple harmful proteins including tau and TDP-43. It also reduced brain inflammation markers and was well-tolerated across all doses, even in genetically high-risk ApoE4 carriers. Annovis is now advancing a focused Phase 3 trial targeting this specific patient profile for up to 18 months.
